Alzheimer’s disease is often described as a slow and steady loss of memory and thinking ability. Many people imagine that once the disease begins, it follows a clear path where symptoms gradually worsen over time.
However, real life is often more complex than this simple picture. A new study from researchers at the Keck School of Medicine of the University of Southern California shows that people experience Alzheimer’s very differently, even in the earliest stages.
The study, published in the journal Alzheimer’s & Dementia, looked at people who did not yet have symptoms but were already at risk of developing Alzheimer’s disease. This stage is called “preclinical Alzheimer’s disease.”
At this point, changes are already happening in the brain, but people still feel normal in their daily lives. Scientists have been very interested in this stage because it may be the best time to prevent or slow down the disease.
The research team followed participants for about six years. During this time, they gave them regular tests to measure memory, attention, and thinking skills. They also collected information from brain scans and blood tests. These tests can show signs of Alzheimer’s in the brain, such as the buildup of certain proteins.
When the researchers analyzed the results, they found something surprising. Instead of one clear pattern, they discovered three very different paths. Some people remained stable, meaning their thinking ability did not get worse and sometimes even improved slightly.
About 70 percent of participants were in this group. Others showed a slow decline, with gradual changes over time. A smaller group experienced fast decline, where their thinking ability dropped more quickly.
This finding is important because many earlier studies focused on the average result across all participants. That approach made it seem like everyone declined at a similar pace. However, this new research shows that the average can hide important differences between individuals.
The researchers also wanted to know if they could predict which group a person would fall into. They looked at biomarkers, which are biological signs in the body that can indicate disease.
One important biomarker they studied was called P-tau217, a substance linked to changes in the brain seen in Alzheimer’s disease. They also examined brain scans, especially focusing on the hippocampus, a part of the brain that plays a key role in memory.
They found that people who declined more quickly tended to have higher levels of P-tau217 and more signs of damage in brain scans at the start of the study.
They also had a smaller hippocampus compared to those who remained stable. By combining these pieces of information, the researchers were able to predict whether someone would stay stable or decline about 70 percent of the time.
Although this is not perfect, it is an important step forward. In the future, doctors may be able to use similar tools to give patients a clearer idea of what to expect. This could help people plan for their future and make better decisions about treatment and care.
The findings also have important implications for clinical trials. Many studies testing new Alzheimer’s treatments assume that all participants will gradually decline over time.
However, if many people remain stable even without treatment, it becomes harder to see whether a drug is actually working. This means researchers may need to design studies differently, focusing more on individuals who are likely to decline.
At the same time, the study raises new questions. Some people did better than expected, while others did worse. The researchers now want to understand why.
It is possible that certain people have protective factors that make them more resilient to the disease. If scientists can identify these factors, they may be able to develop new treatments that help others stay stable for longer.
Overall, this study shows that Alzheimer’s disease is not a simple or predictable condition. It highlights the importance of looking at each person individually rather than relying only on averages. While more work is needed to improve predictions, the research offers hope that one day, care for Alzheimer’s patients will be more personalized and effective.
When we look at the findings closely, it becomes clear that the study challenges traditional thinking about Alzheimer’s. It shows that early-stage disease can remain stable for many people, which is encouraging.
However, the prediction tools are still not precise enough for individual use, and more research is needed to improve them. The study also suggests that clinical trials must change to reflect the true complexity of the disease. Overall, the research is a strong step forward but also highlights how much we still need to learn.
If you care about Alzheimer’s disease, please read studies that bad lifestyle habits can cause Alzheimer’s disease, and strawberries can be good defence against Alzheimer’s.
For more information about brain health, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: University name.
